- Home
- STTK vs ADV Comparison
STTK vs ADV Comparison
Compare STTK & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | ADV |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | 69000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 209.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | STTK | ADV |
|---|---|---|
| Price | $5.99 | $0.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $7.00 | $1.83 |
| AVG Volume (30 Days) | 574.2K | ★ 778.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.49 |
| 52 Week High | $6.13 | $2.11 |
Technical Indicators
Market Signals| Indicator | STTK | ADV |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 57.41 |
| Support Level | $1.85 | $0.51 |
| Resistance Level | N/A | $0.97 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 89.34 | 71.03 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.